Coloplast A/s Class B · OMXCOP:COLO_B
Coloplast A/s Class B — Non-Deal Roadshow (November 2022)
100 slides from Coloplast A/s Class B's roadshow presentation, November 2022
Slide 1: Roadshow presentation FY 2021/22
Roadshow presentation FY 2021/22 Update picture to match FY report Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid FY 2021/22 result with organic growth of 6% and 31% EBIT margin
Solid FY 2021/22 result with organic growth of 6% and 31% EBIT margin1 despite impact from COVID-19 in China and higher input costs REVENUE GROWTH FY 2021/22 highlights Reported revenue (mDKK) Organic growth Reported growth • Organic growth of 6% (5% in Q4) and reported growth in DKK of 16%. Atos Me
Slide 4: Strategic highlights from Strive25 – Sustainable growth leadership
Strategic highlights from Strive25 – Sustainable growth leadership Growth Innovation Atos Medical acquisition 31 January 2022 Chronic Care – Clinical Performance Programme • Adding a new chronic care business segment, Voice and Respiratory Care • The pivotal studies on the new catheter platform, Luj
Slide 5: FY 2021/22 organic growth driven by a good year in Chronic Care
FY 2021/22 organic growth was driven by a good year in Chronic Care with solid growth across all regions, ex. China due to COVID-19 FY 2021/22 revenue by business area FY 2021/22 revenue by geography Business Reported revenue FY Organic growth Share of organic Geographic Reported revenue FY Organic
Slide 6: Ostomy Care grew 5% in Q4 driven by Europe and the US
Ostomy Care grew 5% in Q4 driven by Europe and the US, while China declined due to COVID-19. FY 2021/22 organic growth was 7% Ostomy Care performance Q4 and FY 2021/22 highlights • Q4 organic growth was 5% and reported growth was 9% 13 • All regions contributed to growth excluding China, which remai
Slide 7: Continence Care grew 6% in Q4 and FY 2021/22
Continence Care grew 6% in Q4 and FY 2021/22. Growth in Q4 continued to be impacted by backorders in Collecting Devices Continence Care performance Q4 and FY 2021/22 highlights • Q4 organic growth was 6% and reported growth was 11% • All regions contributed to growth, led by Europe 11 9 9 9 • Solid
Slide 8: Voice & Respiratory Care contributed 9%-points to reported growth in Q4
Voice & Respiratory Care contributed 9%-points to reported growth in Q4 and 6% in FY 2021/22, with high single-digit underlying for the year Voice & Respiratory Care performance Q4 and FY 2021/22 highlights • The Atos Medical acquisition was completed on 31 January 2022, adding a new chronic care se
Slide 9: Wound & Skin Care declined 5% in Q4
Wound & Skin Care declined 5% in Q4 driven by tender phasing and COVID-19 impact in China. FY 2021/22 organic growth was 4% Wound & Skin Care performance Q4 and FY 2021/22 highlights • Q4 organic growth was -5% and reported growth was 1% 17 • Wound Care in isolation declined 6% driven by tender phas
Slide 10: Interventional Urology delivered broad-based growth
Interventional Urology delivered broad-based growth and grew 12% in Q4. Strong performance in FY 2021/22 with organic growth of 9% Interventional Urology performance Q4 and FY 2021/22 highlights • Q4 organic growth was 12% and reported growth was 23% 23 • Men’s Health was the largest contributor to
Slide 11: FY 2021/22 reported revenue was up 16%
FY 2021/22 reported revenue was up 16%, impacted by the inclusion of Atos Medical and currency appreciation FY 2021/22 Revenue development (DKKm) FY 2021/22 highlights • Reported revenue increased by DKK 3,154 million or 16% vs. last year • Organic growth was 6% or DKK 1,203 million, driven by: 712
Slide 12: FY 2021/22 reported EBIT margin of 31%
FY 2021/22 reported EBIT margin of 31%1, reflecting an increased level of commercial activity and amortisation costs related to Atos Medical FY 2021/22 EBIT margin development before special items (%) FY 2021/22 highlights • Gross margin was 69%, on par with last year • Positive impact from: the Ato
Slide 13: FCF development
FCF driven by solid underlying development in earnings, impacted by increase in inventories and cost related to the Atos Medical acquisition FCF development1 FCF development Comments FY 2021/22 highlights • Free cash flow for FY 2021/22 was an outflow of DKK 6,660 million compared to an inflow of DK
Slide 14: FY 2022/23 guidance: Organic growth of 7-8% and EBIT margin of 28-30%
FY 2022/23 guidance: Organic growth of 7-8% and reported EBIT margin of 28-30% GUIDANCE 2022/23 GUIDANCE (DKK)* KEY ASSUMPTIONS • Limited impact from COVID-19 on hospital activity across markets, except for China • Chronic Care excl. China expected to grow largely in line with Strive25 ambitions: Eu
Slide 15: FY 2022/23 guidance breakdown: input cost impact on EBIT margin
FY 2022/23 guidance breakdown: significant negative impact from input cost increases on EBIT margin Revenue growth assumptions Key impacts on gross- and EBIT margin development in 2022/23 68.8 ILLUSTRATIVE In 2022/23, organic growth is expected at 7-8% in constant currencies 66-68% Gross margin (%)
Slide 16: Introduction to Coloplast
Making it easier to be yourself Leading intimate healthcare Introduction to Coloplast Stina | OC user
Slide 17: Coloplast has five business areas all with global sales presence
Coloplast has five business areas all with global sales presence Group revenue 2021/22 by segment1 Group revenue 2021/22 by geography 1 Continence Care 34% European 1 markets 57% Ostomy Care Other developed 38% markets DKK DKK 26% 22.6bn 22.6bn 1 Voice & Respiratory 4 Care Interventional 5% Urology
Slide 18: Coloplast specializes in intimate healthcare needs
Coloplast specializes in intimate healthcare needs Who are our typical users How do we help them? Ostomy Care People who have had their intestine redirected to SenSura® Mio an opening in the abdominal wall Ostomy bag Continence Care People in need of bladder or bowel management SpeediCath® Flex Flex
Slide 19: The Chronic Care model secures a predictable revenue stream
The Chronic Care model secures a predictable revenue stream and stable revenue growth The chronic care user flow Chronic Care condition New user Installed base of users Stable flow of loyal users Solid reimbursement Coloplast group revenues Revenue (DKK bn) Organic growth (%) 10 10 9 8 8 8 8 6 7 7 7
Slide 20: Intimate healthcare is characterized by stable industry trends
Intimate healthcare is characterized by stable industry trends 01. 01. Demographics Surgical and medical trends Growing elderly population Earlier detection and cure, increases customer base for eventually reduces addressable Coloplast products market for Coloplast treatment Limiters Drivers product
Slide 21: Strong market positions in Europe and potential outside Europe
Coloplast has strong market positions in Europe and great commercial potential outside Europe Europe Other developed Ostomy Continence Voice & Respiratory Interventional Wound Emerging Care Care Care (Laryngectomy) Urology Care Addressable market 20-21bn 15-16bn 1–1.5bn 13-14bn 24-26bn Size in DKK 4
Slide 22: Building the consumer healthcare company of the future
We are building the consumer healthcare company of the future Macro Trends Impact Commercial model Ageing population Superior, clinically differentiated products Healthcare consumerism Digital transformation Consumer preference Data and Clinical digital tools preference Price pressure Channel consol
Slide 23: Our Strive25 strategy will drive long-term value creation
Our Strive25 strategy will drive continued long-term value Continence creation through Care Ostomy Wound and revenue and earnings Care Skin Care growth Interventional Voice and Urology Respiratory Care Innovation Leadership, culture 7-9% more than 30% and organization organic growth EBIT margin1 p.a
Slide 24: Strive25 emphasis on improving environmental performance
With Strive25 we put emphasis on improving our environmental performance, while continuing our ongoing commitments Our mission Making life easier for people with intimate healthcare needs Our 2025 priority Our 2025 priority Improving products Reducing emissions1 and Packaging1 90% of packaging recyc
Slide 25: Incremental investments of up to 2% of revenue in Strive25 period
We will continue to support organic growth through yearly incremental investments of up to 2% of revenue in the Strive25 period Key Investment Decision Drivers Key Investment Areas We expect to invest up to 2% Economics & Government Innovation of revenue in incremental OPEX investments Chronic Care
Slide 26: Actively pursue M&A opportunities as a lever for growth
We will actively pursue M&A opportunities as a lever for long-term growth Opportunity Systematic based screening Large plays Channel expansion Portfolio expansion & Early stage adjacencies technologies 26
Slide 27: Key enablers supporting the commercial model in Chronic Care
We have built key enablers to support the commercial model in our Chronic Care businesses Commercial model Key enablers Superior, clinically Direct Businesses differentiated products Coloplast Consumer Care Consumer preference Data and digital tools Clinical preference Direct to Consumer Data & Digi
Slide 28: Direct business in Chronic Care drives improved outcomes
Direct business in Chronic Care serving consumers drives improved outcomes and is a vital component of our growth Direct presence in top 5 markets and strategic rationale Coloplast Consumer presence (incl. patient support programme, Coloplast® Care) Control and continuity 1 of product supply ~30% MS
Slide 29: Clinical Performance Programme to tackle biggest user issues
We have initiated a very ambitious Clinical Performance Programme to tackle the biggest issues users face 45 of users describe UTIs are their %* 2.7 UTIs per user on average every year1 93 % worry about leakage2 greatest challenge in life1 1 Source: Coloplast IC user survey, January 2016 (n=2,942),
Slide 30: Solid progress on Heylo and Luja; new ostomy platform discontinued
Solid progress on Heylo™ and Luja™; development of the new ostomy platform is discontinued Status November 2022 Expected launch Heylo™ CE mark has been granted Product launch expected digital leakage Payer pilot studies in Germany and the UK progressing as in 2023 notification system planned, with g
Slide 31: Leakage remains the biggest challenge for our users
Leakage remains the biggest challenge for our users 91% of people with a stoma worry about leakage1 40 % of users experience leakage onto their clothes every month2 Heylo addresses the mental burden caused by fear of leakage Control and peace of mind 1. Claessenes et. al. Gastrointestinal Nursing 20
Slide 32: Data on Heylo is promising
Data on Heylo™ is promising. Pre-pilot study shows high product performance and user preference Product performance & user experience1 Quality of life and future use1 reduction in worry of leakage 92%* % +9 emotional impact of leakage significant improvement to less leakage episodes 85 %** % 96 secu
Slide 33: Clinical program supports launches and reimbursement applications
The clinical program supports national launches, reimbursement applications and generates user insights Single-arm confirmatory study, n=100 Show benefit to support Drug Tariff application: • Leakage onto clothes • Quality of Life • Healthcare utilisation • Support reimbursement in DE & UK Cross-ove
Slide 34: Preventing UTIs remains one of the biggest unmet needs
Preventing UTIs % remains one of the 45% 48 biggest unmet of users consider of users are UTIs to be their worried whether needs we need to greatest challenge1 they have emptied solve for in IC their bladder4 IC users have 2-3 UTIs on average per year…2 …over a lifetime users will have up to 1 IC Val
Slide 35: Luja catheter platform with Micro-hole Zone Technology
Luja™, our new catheter platform with Micro-hole Zone Technology™ addresses the key UTI risk factors UTI Risk Factor Model1 UTI risk factors addressed by Luja™ Intermittent General patient catheterisation conditions UTI risk factor: UTI risk factor: Non-hygienic technique Urethral trauma UTI risk fa
Slide 36: Comprehensive clinical program behind Luja
Comprehensive clinical program behind Luja™ to demonstrate the clinical relevance and difference Pivotal studies 3 multinational pivotal studies2 involving 150+ users demonstrating the impact on the key risk factors of UTI. Pilot studies Multicenter, randomised cross 8 studies comparing Luja over tr
Slide 37: Profitability supported by scalability and efficiency gains
Profitability supported by scalability and efficiency gains enabling additional innovation and commercial investments Gross Profit development, %* Cost item Development, in % of revenue* 1.4%-points 28.7 29.0 28.7 28.2 30.1 28-30 Distribution 1.5%-points 67.3 67.7 68.0 68.5 68.8 ~68 0.5%-points 4.2
Slide 38: Automation, procurement and scale key to Global Operations
Automation, procurement and scale are key to bringing Global Operations to the next level 1. Automation to mitigate growth in blue-collar FTE 9% ~600 >1,000 DKK ~450m # of FTE release ~500 CAPEX investment over ~200 through automation four years (19/20 – 22/23) Salary1 (Direct labour) 19/20 20/21 21
Slide 39: Global Business Support and IT landscape enables scaling
A global Business Support and IT landscape enables Coloplast to scale faster and more efficiently and integrate Atos Medical into the Group Global Business Services Global business services handle the majority of all global support % of group processes 100% ~90% 100% 100% IT infrastructure Finance /
Slide 40: EBIT margin development drivers
EBIT margin development continues to be a function of growth, scalability, cost discipline and investment activity EBIT margin (%) Illustrative Future drivers of EBIT margin EBIT will be positively impacted by: Leverage effect on fixed costs e.g. distribution, admin and R&D costs >30% especially dri
Slide 41: Continued strong free cash flow development during Strive25
Continued strong development in free cash flow during the Strive25 strategy period Taxation Net working capital CAPEX2 Reported tax rate Net working capital, % of revenue CAPEX DKKm Depreciation and amortisation, % of revenue CAPEX, % of revenue 5% 5% 5% 6% 4% 4% 5% 4% 4% 4% 4% 23% 24% 23% 24% 25% ~
Slide 42: Attractive cash returns despite investments and Atos acquisition
We will continue to provide attractive cash returns despite investments in commercial activities and the Atos Medical acquisition Coloplast cash distribution to investors Highlights Dividends paid out in the year (DKKm) (1) Share buy-back (DKKm) Pay-out ratio (%) (2) • Coloplast returns excess liqui
Slide 43: Coloplast can continue to deliver stable shareholder returns
In sum, we believe Coloplast can continue to deliver stable shareholder returns through ... Organic growth and EBIT margin development Highlights 31% • Stable market trends in our Chronic Care business 10% 6% • Strong Coloplast Care retention program 9% and innovative DtC activities 06/07 08/09 10/1
Slide 44: Introduction to Atos Medical
Introduction to Atos Medical The global market leader in laryngectomy | Atos user
Slide 45: Atos Medical is the global pioneer within Laryngectomy
Atos Medical is the global pioneer within Laryngectomy and has shaped the market for the past +30 years Key market and business highlights Revenue by segment and geography Laryngectomy Tracheostomy Other ~50,000 New total laryngectomies per year Organic CAGR ~8% ~85% Global Laryngectomy market share
Slide 46: Atos improves the lives of patients following Total Laryngectomy
Atos improves the lives of patients following Total Laryngectomy procedures A Total Laryngectomy is a non-elective After surgery, a Voice Prosthesis (VP) is inserted by a healthcare professional, surgery performed in the advanced and the patient applies the Heat- and Moisture Exchanger (HME) and adh
Slide 47: Significant untapped potential in the laryngectomy market
There is significant untapped potential in the laryngectomy market today, which we will seek to eliminate The laryngectomy market, DKKbn Low level of market penetration due to: We will eliminate the ‘white space’ by: Lack of clinical standards in existing 01 markets outside of Northern Europe Settin
Slide 48: Tracheostomy patients have similar needs as Laryngectomy patients
Tracheostomy patients have similar needs as Laryngectomy patients, as they are both breathing through a neck stoma A Tracheostomy is a surgical The Tracheostomy patient journey starts with a cannula insertion, which can be procedure that creates an opening in reversed at any stage the neck for direc
Slide 49: Atos Medical financial assumptions
Atos Medical financial assumptions Organic growth and • Organic growth 8-10% EBITDA margin • EBITDA margin in the mid-30s level EPS impact • Increasingly EPS accretive from FY 2022/23 • Estimated run-rate operational synergies of up to DKK 100m from utilising Coloplast Synergies infrastructure with
Slide 50: Appendices
Leading intimate healthcare Leading intimate healthcare Appendices Tabitha | IC user
Slide 51: The Coloplast share
The Coloplast share (COLO-B.CO) Holders of A shares and family 1 Danish institutions Foreign institutions Coloplast A/S Coloplast share listed on Nasdaq Copenhagen Other shareholders since 1983 Non-registered shareholders 4.0% 7.0% ~171.8 billion DKK (~23 billion USD) market cap @ ~809.0 DKK per sha
Slide 52: Capital structure
Capital structure Comments Net interest bearing debt • Overall policy is that excess liquidity is returned to shareholders through a 2.3x 2.0x combination of dividends and share buy-backs • Interest bearing debt will only be raised 18,091 in connection with a major acquisition, 1.0x 0.2x 0.3x such a
Slide 53: Q4 organic growth of 5% driven mostly by Chronic Care
Q4 organic growth of 5% driven mostly by Chronic Care, while WSC hampered growth. China OC and WSC remains impacted by COVID-19 Q4 2021/22 revenue by business area Q4 2021/22 revenue by geography Business Reported revenue Q4 Organic growth Share of organic Geographic Reported revenue Q4 Organic grow
Slide 54: Q4 reported growth was up 19%
Q4 reported growth was up 19%, with ~9%-points positive impact from the Atos acquisition and ~5%-points impact from currencies Revenue development (DKKm) Q4 2021/22 highlights • Reported revenue increased by DKK 959 million, or 19% compared to Q4 2020/21 • Q4 organic growth was 5% or DKK 244 million
Slide 55: Reported EBIT margin of 30% in Q4
Reported EBIT margin of 30%1 in Q4, reflecting a normalisation of commercial activity, increasing input costs, and Atos amortisation costs EBIT margin development before special items (%) Q4 2021/22 highlights • Q4 gross margin was 69%, on par with Q4 last year • Positive impact from: the Atos Medic
Slide 56: Key value ratios
Key value ratios Profitability drivers Free Cash Flow drivers 32.7 36.3 36.2 36.8 31.9 32.3 34.7 34.6 34.7 31.2 32.0 31.5 28.7 29.0 28.1 28.7 28.2 30.1 25.2 25.4 23.4 23.6 23.4 23.7 4.0 4.0 4.2 4.1 3.9 4.5 4.4 5.0 5.2 5.0 4.1 3.5 3.7 3.9 3.9 3.8 3.9 3.8 16/17 17/18 18/19 19/20 20/21 21/22 16/17 17/1
Slide 57: Coloplast revenue development by business area
Coloplast revenue development by business area Ostomy Care Interventional Urology Voice & Respiratory Care 9 8 6 6 10 19 6 7 7 13 16 5 4 10 14 8,620 6 6%-p 7,841 9 7,166 7,538 10 6,643 Contribution to reported -7 growth 1,970 2,097 2,424 1,740 1,835 NA NA NA NA 1,203 17/18 18/19 19/20 20/21 21/22 17
Slide 58: Coloplast revenue development by geography and total
Coloplast revenue development by geography and total Europe Other Developed Markets 6 6 4 15 2 5 6 5 2 4 16 21 12,916 11 10,573 10,820 11,261 8 9,941 4 11 5 6 6 3 4,785 5,775 3,791 4,380 4,644 17/18 18/19 19/20 20/21 21/22 17/18 18/19 19/20 20/21 21/22 FY reported growth rate includes 8%-p impact fr
Slide 59: Segment operating profit
Segment operating profit (Excludes shared/non-allocated costs) Chronic Care Interventional Urology Wound & Skin Care Voice & Respiratory Care Ostomy and Continence Care • Voice & Respiratory Care is 57 59 59 59 58 Coloplast’s new business area, added with the acquisition of Atos Medical. 2,397 2,500
Slide 60: FY 2021/22 Atos Medical impact on EBIT
FY 2021/22 Atos Medical impact on EBIT Atos Medical acquisition EBIT impact 35% 32% 3% 31% 31% 0% 1% 29% 1% 1% DKK 171 DKK 300 DKK 152 DKK 108 DKK 670 million million million million million EBIT margin Special items Mesh provision EBIT margin Atos EBIT FY Amortisation EBITA Depreciation EBITDA afte
Slide 61: Exchange rate exposure FY 2022/23 and hedging policy
Exchange rate exposure FY 2022/23 and hedging policy Revenue FX exposure 2022/23(1) 12 months exposure from 10% initial exchange rate drop(1) Other 18% -490 USD -220 EUR 36% CNY, JPY, AUD, BRL & ARS -320 12% GBP -220 HUF 0 130 14% GBP 20% Revenue (DKKm) EBIT (DKKm) USD Foreign exchange rate guidance
Slide 62: US Mesh litigation – Overview of financial impact
US Mesh litigation – Overview of financial impact P&L – overview of special items related to the Mesh Balance Cash flow litigation Assets Actual/Expected cash flow, DKKbn 13/14 14/15 15/16 16/17 17/18 18/19 19/20 20/21 21/22 Restricted cash, DKKbn 0.5 0.5 EBIT (before special items) 4,147 4,535 4,84
Slide 63: Stable global health reforms environment
Stable global health reforms environment Europe Rest of World • Netherlands: Reimbursement pressure on OC and CC • U.S.: Reimbursement pressure on OC and CC (Managed Care) • France: Reimbursement pressure on WC 63 Reimbursement pressure
Slide 64: CARE helps increase retention and improve product compliance
CARE helps us increase retention and improve product compliance We co-develop CARE content with CARE is a personal and “high- Global program with shared local clinicians touch” program infrastructure Advisors available on phone Clinically validated content and call protocol - ERP Website with reliab
Slide 65: DtC marketing program reaches into the community
With our DtC marketing program we reach into the community We operate in numerous channels to expose our …and with the reach we get several benefits service and product offering… Expose innovative products Ensure product accessibility Ensure successful experience 65
Slide 66: Generic model for distribution and reimbursement
The generic model for distribution and reimbursement of our products Prescription & Insurance Product Reimbursement price Prescription & Insurance Payer Distribution Consumer $ Product 66
Slide 67: Interventional Urology's revenue is balanced geographically
Interventional Urology’s revenue is balanced geographically and across the four business areas Interventional Urology at a Glance 15-20% market share in global market of DKK 13-14bn FY 21/22 market growing 3-5% annually 11% Coloplast position, FY 20/21 of Coloplast sales Endourology Men’s Health Wom
Slide 68: Interventional Urology select products
Coloplast Interventional Urology is split into four business areas Men’s Women’s Bladder health Endourology & surgery Health Health • Erectile Dysfunction • Stress Urinary Incontinence • Stone Management • Bladder Drainage • Male Incontinence (SUI) • Transurethral • Benign prostatic hyperplasia • Te
Slide 69: Strong presence in Interventional Urology with room to capture share
We have a strong presence in our categories in Interventional Urology but there is room to capture market share 1 Men’s Health Women’s Health Endourology Bladder Health & 1 Surgery Inflatable Penile Male Stress urinary Pelvic organ Prosthesis (IPP) incontinence incontinence prolapse Fragmented Compe
Slide 70: Refined product roadmap in Interventional Urology
We are executing a refined product roadmap in Interventional Urology aligned to Strive25; progress is tracking to key milestones Strategy Description Men’s Health Women’s Health Endourology Projects that address regulatory Cadence of stone Strengthen core requirements, close gaps and maintain IPP En
Slide 71: Growth through product and therapy expansion
We will deliver growth through product and therapy expansion Tissue Fixation System Implantable Tibial Nerve TECHNOLOGY ASSESSMENT Stimulator Launching 22/23 Launching 25/26 ACTIVELY PURSUING POP SUI AUS Cancer ED IU Today OAB Endo Endo Consum- ables Laser Endo Visualization Soprano® BPH Hybrid Guid
Slide 72: Acquisition of Nine Continents to enter the OAB market
With the acquisition of Nine Continents, we are executing on the option to enter the attractive OAB market with Intibia Overactive bladder (OAB) market Why Implantable Tibial Nerve Stimulation (ITNS)? Less invasive ITNS complete in single procedure +80m people globally suffer from OAB symptoms proce
Slide 73: Global Advanced Wound Care market remains large and growing
The global Advanced Wound Care market remains large and growing The Advanced Wound Care market remains a significant Silicone Foams and Gelling Fibers are the two biggest value pool and is expected to grow despite the pandemic categories and grow faster than the market Market size in DKKbn Market si
Slide 74: The Wound & Skin Care 2025 strategic plan
The Wound & Skin Care 2025 strategic plan Scale our China business Build on positive momentum in EU by strengthening our commercial in silicone and 3DFit Technology and foundation and accelerate in silicone increase share of voice in selected with 3DFit Technology markets Scale our US business in Ac
Slide 75: In US Ostomy Care we continue to win across patient pathway
In US Ostomy Care we continue to win across patient pathway We have gained significant share over the last years … as we work on multiple fronts to win across the patient pathway 3-5 days >60 days ~10 years Bags & Plates acute share Acute Post-acute Community +10%-pts Patients’ first (incl. HHA) Lon
Slide 76: Awarded access to Vizient and Premier GPOs
Coloplast has been awarded access to Vizient and Premier GPOs, ensuring a level playing field in ~75% of acute accounts Coloplast has been awarded access to Vizient and Premier, the two largest GPOs in the US Acute Estimated Contract start Contract Contract members1 Acute share2 date length type TM*
Slide 77: Sustainability - key priorities and actions
Sustainability - key priorities and actions Improving products Reducing emissions Responsible and packaging operations Why is this a key priority: Why is this a key priority: Why is this a key priority: As a manufacturer of medical products made primarily As a growing company, we are challenged by a
Slide 78: FY 21/22 progress on key sustainability ambitions
FY 21/22 progress on key sustainability ambitions – carbon emission targets approved by the SBTi* in June 2022 Improving products and packaging Reducing emissions2 Responsible operations 2025 FY FY 2025 FY FY 2025 FY FY Ambition 21/22 20/21 Ambition 21/22 20/21 Ambition 21/22 20/21 100% 2.4 2.2 90%
Slide 79: Introducing Ostomy Care
Introducing Key products Ostomy Care Disease areas • Colorectal cancer (est. 45%) • Bladder cancer (est. 10%) SenSura® Mio Concave SenSura® Mio Convex SenSura® Mio • Diverticulitis (est. 15%) Launched in 2018-2019 Launched in 2015 Launched in 2014 • Inflammatory bowel disease (est. 10%) • Other (est
Slide 80: Ostomy Care Supporting Products
Introducing Key products Ostomy Care Supporting Products Market fundamentals Brava® Protective Seal Brava® Skin Barrier Brava® Elastic Tape Designed for leakage and skin Reducing skin problems Elastic so it follows • Market size of DKK 3-4bn protection without affecting adhesion the body and • Marke
Slide 81: Introducing Continence Care
Introducing Continence Key products Care Disease areas • Spinal Cord Injured, SCI SpeediCath® Flex Set SpeediCath® Navi SpeediCath® Flex SpeediCath® Compact Eve • Spina Bifida, SB Intermittent Set catheter Intermittent catheter Intermittent catheter Intermittent catheter • Multiple Sclerosis, MS Lau
Slide 82: Introducing Bowel Management
Introducing Key products Bowel Management Disease areas Faecal incontinence (management products only) Peristeen® Plus Anal Irrigation Peristeen® Anal Irrigation Anal plug Launched in 2021 Launched in 2003 Launched in 1995 Customer groups Updated in 2011 • Spinal Cord Injured, SCI • Spina Bifida, SB
Slide 83: Laryngectomy
Introducing Key products - Laryngectomy Voice & Respiratory Care Provox® Life ™ Laryngectomy Heat and Moisture Exchangers (HMEs) Home Go Night Protect Energy Free hands Disease areas • People that have undergone a total Provox® Life ™ laryngectomy, a typical treatment for Adhesive advanced laryngeal
Slide 84: Tracheostomy
Introducing Voice & Respiratory Care Tracheostomy Disease areas Key products - Tracheostomy • Performed when the airways are restricted, e.g., during an emergency when the airways are Portfolio expansion blocked, or when a disease or other problem • Strengthened the tracheostomy makes normal breathi
Slide 85: Interventional Urology
Introducing Key products Interventional Urology Surgical treatment of urological disorders Disease areas Titan® Touch Inflatable Penile Prosthesis Altis® single incision sling • Urinary incontinence Launched in 2013, Men’s health Launched in 2012 Women’s health – Surgical Urology • Pelvic organ prol
Slide 86: Wound Care
Key products Introducing Wound Care Disease areas Chronic wounds Biatain® Silicone Non-Border Biatain® Fiber Biatain® Contact • Leg ulcers Silicone foam dressing without a Reinforced gelling fiber. Silicone contact layer. • Diabetic foot ulcers border. Launched in 2021 Launched in 2020 Launched in 2
Slide 87: Skin Care
Introducing Key products Skin Care Disease areas • Moisture associated skin damage Sween® EasiCleanse® Bath • Incontinence Broad line of skin care products Disposable bathing wipes • Skin folds & obesity Designed to increase consistency of care Improves patient experience • Prevention of skin impair
Slide 88: US Skin Care
At a glance US Skin Care US Skin Care market Market Market drivers drivers andand limiters limiters + +AgingAging and obese population and obese population US market size estimated + +CMSCMSValueValue BasedBased Purchasing Purchasing at DKK 4-5bn with 2-4% growth + +Increased focusfocus Increased on
Slide 89: Coloplast organisation divided into Chronic Care and Strategic Business Units
The Coloplast organisation is divided into Chronic Care and Strategic Business Units, running on shared global business support functions Coloplast Group Chronic Care Strategic Business Unit Wound Interventional Voice & Ostomy Care Continence Care & Skin Care Urology Respiratory Care Marketing Marke
Slide 90: The Coloplast Executive Leadership Team
The Coloplast Executive Leadership Team Kristian Villumsen President, CEO (Born 1970) With Coloplast since 2008 Nicolai Buhl Andersen Anders Lonning-Skovgaard Paul Marcun Dorthe Rønnau Allan Rasmussen EVP, Innovation EVP, CFO EVP, Growth SVP, People & Culture EVP, Operations (Born 1969) (Born 1972)
Slide 91: Income statement
Income statement DKKm FY 2020/21 FY 2021/22 Change Revenue 19,426 22,579 16% Gross profit 13,313 15,529 17% SG&A costs -6,247 -7,802 25% R&D costs -755 -866 15% Other operating income/expenses 44 49 11% Operating profit (EBIT) before special items 6,355 6,910 9% Special items -200 -471 136% Operatin
Slide 92: Balance sheet
Balance sheet DKKm 30 Sep 2021 30 Sep 2022 Change Balance, total 15,841 34,956 121% Assets Non-current assets 8,847 26,184 196% Current assets 6,994 8,772 25% of which: Inventories 2,428 3,187 31% Trade receivables 3,212 3,940 23% Marketable securities, cash, and cash equivalents 674 633 -6% 675 Equ
Slide 93: Cash flow
Cash flow DKKm FY 2020/21 FY 2021/22 Change EBIT 6,155 6,439 5% Amortisation 129 260 102% Depreciation 663 670 1% Adjustment for other non-cash operating items -31 56 nm Change in working capital -75 -849 nm Net interest payments -50 -362 nm Paid tax -1,501 -1,115 -26% Cash flow from operations 5,29
Slide 94: Manufacturing setup
Manufacturing setup Production by country (Volume)¹ 3% 5% Hungary Hörby 0% Mørdrup Tatabánya China 11% Minneapolis Nieder-Olm 4% Nyirbátor Mankato Sarlat US/France Denmark Zhuhai Costa Rica Costa Rica 77% Atos (SE/DE) COGS by cost type² 9% 19% Salary - Direct 12% Salary - Indirect 5% Materials (RM &
Slide 95: Production sites
Production sites Hungary China Tatabánya Zhuhai • Ostomy care products • Continence care products • Adhesives • Ostomy care products • Continence care products • Machine building • Interventional Urology products • Number of employees in production: ~900 • Number of employees in production: ~1,800 T
Slide 96: Production sites
Production sites Denmark Germany Mørdrup Nieder-Olm • Pilot development work Ostomy care, • Specialised production Continence care and Wound care • Research & Development centre and • Adhesives production manufacturing of tracheostomy products • Number of employees in production: ~150 • Number of em
Slide 97: Global Operations Plan 6 to be announced in 2023
Our Global Operations Plan 6 will be announced in 2023, key themes will be resilience and optimizing the footprint Moving focus of GOP6 to further strengthening our model while delivering continued leverage effect on fixed costs and efficiency improvement 2008 2009 2012 2017 2020 2023-2026 Turn-arou
Slide 98: Coloplast Sponsored Level 1 ADR programme
Coloplast Sponsored Level 1 ADR programme Coloplast Sponsored ADR Programme Benefits of a Coloplast ADR programme to US Investors: • Coloplast has established a sponsored ADR programme in the US, as a Symbol CLPBY service to US investors by offering an alternative way to trade Coloplast shares, whil
Slide 99: Contact Investor Relations
Contact Investor Relations Holtedam 1 DK-3050 Humlebæk Denmark Aleksandra Dimovska Kristine Husted Munk Margrethe Borgbjerg Director, Investor Relations Senior Manager, Investor Relations Coordinator & PA, Investor Relations Tel. direct: +45 4911 2458 Tel. direct: +45 4911 3266 Tel. direct: +45 4911
Slide 100: Mission, values and vision
Mission Making life easier for people with intimate healthcare needs Values Closeness… to better understand Passion… to make a difference Respect and responsibility… to guide us Vision Setting the global standard for listening and responding